drugset / Trial / NCT02980042
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least two infusions of rituximab, six months apart and are willing to be switched to ocrelizumab compared to a 100 patients who are continuing on rituximab as a comparison cohort from the clinic population treated as part of clinical care.
Timeline
- Start
- 2017-01-01
- Primary completion
- 2019-03-06
- Completion
- 2019-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ocrelizumab | Monoclonal antibody | 600 mg | Intravenous |
| Comparator | Rituximab | Monoclonal antibody | 500 mg | Intravenous |
| Comparator | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |